Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2025

SKU ID : DEL-DIMI0132

Publishing Date : 01-Dec-2017

No. of pages : 70

PRICE
5750
17250


  • “Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Malignant Mesothelioma for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Malignant Mesothelioma . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Malignant Mesothelioma for 7 major markets.

    The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Malignant Mesothelioma market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Malignant Mesothelioma , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

    According to , the forecasted patient population of Malignant Mesothelioma for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Malignant Mesothelioma 7MM market size is estimated to be USD XX by 2025.The Report will help in enhanced understanding of the Malignant Mesothelioma market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

    Key Coverage

    • Understanding historical and forecasted epidemiological data for Malignant Mesothelioma covering 7MM from 2015-2025.
    • Segment level epidemiology and market split for Malignant Mesothelioma .
    • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Malignant Mesothelioma .
    • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Malignant Mesothelioma market trends.
    • Thorough market distribution based on market share for Malignant Mesothelioma .

    Reasons to buy

    • The report will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.
    • To understand the future market competition in the Malignant Mesothelioma market and Insightful review of the key market drivers and barriers.
    • Organize sales and marketing efforts by identifying the best opportunities for Malignant Mesothelioma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.


    Detailed TOC of Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2025

    1. Report Introduction
    2. Malignant Mesothelioma Market Overview at a Glance
    2.1. Total Market Share Distribution of Malignant Mesothelioma for 7 MM in 2016
    2.2. Total Market Share Distribution of Malignant Mesothelioma for 7 MM in 2025
    3. Malignant Mesothelioma
    3.1.1. Overview
    3.1.2. Symptoms
    3.1.3. Pathophysiology
    3.1.4. Staging
    3.1.5. Diagnosis
    3.1.6. Treatment
    4. Epidemiology and Patient Population
    4.1.1. United States
    4.1.1.1. Diagnosed Cases of Malignant Mesothelioma in United States
    4.1.2. Germany
    4.1.2.1. Diagnosed Cases of Malignant Mesothelioma in Germany
    4.1.3. France
    4.1.3.1. Diagnosed Cases of Malignant Mesothelioma in France
    4.1.4. Italy
    4.1.4.1. Diagnosed Cases of Malignant Mesothelioma in Italy
    4.1.5. Spain
    4.1.5.1. Diagnosed Cases of Malignant Mesothelioma in Spain
    4.1.6. United Kingdom
    4.1.6.1. Diagnosed Cases of Malignant Mesothelioma in United Kingdom
    5. Treatment Algorithm
    5.1.1. Treatment Guidelines/Practices
    6. Marketed Drugs for Malignant Mesothelioma
    6.1. Drug 1: Company A
    6.1.1. Drug Description
    6.1.2. Mechanism of Action
    6.1.3. Regulatory Milestones
    6.1.4. Advantages & Disadvantages
    6.1.5. Safety and Efficacy
    6.1.6. Product Profile
    6.1.7. Patent Status
    6.2. Drug 2: Company B
    6.2.1. Drug Description
    6.2.2. Mechanism of Action
    6.2.3. Regulatory Milestones
    6.2.4. Advantages & Disadvantages
    6.2.5. Safety and Efficacy
    6.2.6. Product Profile
    6.2.7. Patent Status
    7. Emerging Therapies
    7.1. Drug 3: Company C
    7.1.1. Description
    7.1.2. Regulatory Milestones
    7.1.3. Advantages & Disadvantages
    7.1.4. Product Profile
    7.1.5. Launch Date
    7.1.6. Clinical Development
    7.1.7. Clinical Pipeline Activity
    7.1.8. Ongoing Trials Information
    7.1.9. Clinical Trial by Phase
    7.2. Drug 4: Company B
    7.2.1. Description
    7.2.2. Regulatory Milestones
    7.2.3. Advantages & Disadvantages
    7.2.4. Product Profile
    7.2.5. Launch Date
    7.2.6. Clinical Development
    7.2.7. Clinical Pipeline Activity
    7.2.8. Ongoing Trials Information
    7.2.9. Clinical Trial by Phase
    8. Overview of Total Malignant Mesothelioma Market (2016 & 2025)
    9. Malignant Mesothelioma : Country-Wise Market Analysis
    9.1. United States
    9.1.1. Historical Market Size (2015-2016)
    9.1.2. Forecasted Market Size (2017-2025)
    9.2. Germany Market Size
    9.2.1. Historical Market Size (2015-2016)
    9.2.2. Forecasted Market Size (2017-2025)
    9.3. France Market Size
    9.3.1. Historical Market Size (2015-2016)
    9.3.2. Forecasted Market Size (2017-2025)
    9.4. United Kingdom Market Size
    9.4.1. Historical Market Size (2015-2016)
    9.4.2. Forecasted Market Size (2017-2025)
    9.5. Spain Market Size
    9.5.1. Historical Market Size (2015-2016)
    9.5.2. Forecasted Market Size (2017-2025)
    9.6. Italy Market Size
    9.6.1. Historical Market Size (2015-2016)
    9.6.2. Forecasted Market Size (2017-2025)
    9.7. Japan Market Size
    9.7.1. Historical Market Size (2015-2016)
    9.7.2. Forecasted Market Size (2017-2025)
    10. Market Drivers
    11. Market Restraints
    12. Appendix
    13. Report Methodology
    14. Consulting Services
    15. Disclaimer
    16. About DelveInsight

    List of Figures, Tables and Charts Available in Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2025

    Table 1: Diagnosed Cases Malignant Mesothelioma in United States (2015-2025)
    Table 2: Diagnosed Cases Malignant Mesothelioma in Germany (2015-2025)
    Table 3: Diagnosed Cases Malignant Mesothelioma in France (2015-2025)
    Table 4: Diagnosed Cases Malignant Mesothelioma in United Kingdom (2015-2025)
    Table 5: Diagnosed Cases Malignant Mesothelioma in Spain (2015-2025)
    Table 6: Diagnosed Cases Malignant Mesothelioma in Italy (2015-2025)
    Table 7: Diagnosed Cases Malignant Mesothelioma in Japan (2015-2025)
    Table 8: List of Marketed Drugs for Malignant Mesothelioma
    Table 9: List of Pipeline Phase III Drugs for Malignant Mesothelioma
    Table 10: Drug 1, Clinical Trials by Zone, 2017
    Table 11: Clinical Trials by Trial status, 2017
    Table 12: Drug 2, Clinical Trials by Zone, 2017
    Table 13: Clinical Trials by Trial status, 2017
    Table 14: Drug 3, Clinical Trials by Zone, 2017
    Table 15: Clinical Trials by Trial status, 2017
    Table 16: United States Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 17: Germany Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 18: France Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 19: United Kingdom Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 20: Spain Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 21: Italy Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Table 22: Japan Market Size of Malignant Mesothelioma in USD, Million (2015-2025)



    Figure 1: Diagnosed Cases Malignant Mesothelioma in United States (2015-2025)
    Figure 2: Diagnosed Cases Malignant Mesothelioma in Germany (2015-2025)
    Figure 3: Diagnosed Cases Malignant Mesothelioma in France (2015-2025)
    Figure 4: Diagnosed Cases Malignant Mesothelioma in United Kingdom (2015-2025)
    Figure 5: Diagnosed Cases Malignant Mesothelioma in Spain (2015-2025)
    Figure 6: Diagnosed Cases Malignant Mesothelioma in Italy (2015-2025)
    Figure 7: Diagnosed Cases Malignant Mesothelioma in Japan (2015-2025)
    Figure 8: List of Marketed Drugs for Malignant Mesothelioma
    Figure 9: List of Pipeline Phase III Drugs for Malignant Mesothelioma
    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
    Figure 11: Clinical Trials by Trial status, 2017
    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
    Figure 13: Clinical Trials by Trial status, 2017
    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
    Figure 15: Clinical Trials by Trial status, 2017
    Figure 16: United States Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 17: Germany Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 18: France Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 19: United Kingdom Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 20: Spain Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 21: Italy Market Size of Malignant Mesothelioma in USD, Million (2015-2025)
    Figure 22: Japan Market Size of Malignant Mesothelioma in USD, Million (2015-2025)

    Latest REPORTS

    Related REPORTS